Alpha 2.0
Login Register
» Articles » PMID: 36103364

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Overview
Journal Oncologist
Publisher Oxford University Press
Specialty Oncology
Date 2022 Sep 14
PMID 36103364
Authors
Joseph W Franses
Mir Lim
Adam M Burgoyne
Kabir Mody
Jochen Lennerz
Jeremy Chang
Robin Imperial
Stacey N Dybel
Thi M Dinh
Jude Masannat
Caroline M Weipert
David Hsiehchen
Affiliations
Soon will be listed here.
Abstract

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

Citing Articles

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.

Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C Biomark Res. 2024; 12(1):26.

PMID: 38355603 PMC: 10865587. DOI: 10.1186/s40364-023-00535-z.

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.

Kopystecka A, Patryn R, Lesniewska M, Budzynska J, Koziol I Int J Mol Sci. 2023; 24(11).

PMID: 37298294 PMC: 10253340. DOI: 10.3390/ijms24119342.

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.

Ji J, Ha S, Lee D, Sankar K, Koltsova E, Abou-Alfa G Int J Mol Sci. 2023; 24(8).

PMID: 37108802 PMC: 10144688. DOI: 10.3390/ijms24087640.

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.

Gabbia D, De Martin S Int J Mol Sci. 2023; 24(4).

PMID: 36834851 PMC: 9960420. DOI: 10.3390/ijms24043441.

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.

Li M, Li L, Zheng J, Li Z, Li S, Wang K Mol Cancer. 2023; 22(1):37.

PMID: 36810071 PMC: 9942319. DOI: 10.1186/s12943-023-01745-7.

References
1.
Kazdal D, Endris V, Allgauer M, Kriegsmann M, Leichsenring J, Volckmar A . Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol. 2019; 14(11):1935-1947. DOI: 10.1016/j.jtho.2019.07.006. View
2.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope F . Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020; 10(12):1808-1825. PMC: 7710563. DOI: 10.1158/2159-8290.CD-20-0522. View
3.
Chan L, Tsui Y, Ho D, Ng I . Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2021; 82:134-149. DOI: 10.1016/j.semcancer.2021.02.015. View
4.
Si H, Kuziora M, Quinn K, Helman E, Ye J, Liu F . A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clin Cancer Res. 2020; 27(6):1631-1640. DOI: 10.1158/1078-0432.CCR-20-3771. View
5.
Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View